Slower ramp-up of new beds impacting margins
The large bed addition plan (~1,000 beds) may face ramp-up delays, with Manesar already incurring an EBITDA loss of INR 12 crore in Q4.
FORTIS / Q4-FY25 / risks
Keep the risk register visible.
Fortis Healthcare · Material risks, their source context, and severity in the latest available quarter.
Research layer active
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Risk intelligence
Material risks this quarter
medium
Legal and legacy costs persist
Legal and other legacy costs continue to consume ~1% of EBITDA, with no near-term resolution expected for the Delhi High Court case.
Diagnostic revenue growth may lag expectations
Despite margin improvement, Agilus revenue growth has been low single-digit; management's double-digit growth target may be challenged by competitive pressures.
Geopolitical risks to international patient revenue
International patient revenue growth of 17% may not sustain due to geopolitical tensions, though management expects stable contribution.